- If you are wondering whether Kiniksa Pharmaceuticals International at around US$52.99 is genuinely good value or just riding sentiment, the starting point is to look closely at what the current price implies.
- The stock shows recent returns of 23.1% over 7 days, 10.1% over 30 days, 26.2% year to date and 91.0% over the past year, which naturally raises questions about how much of the story is already reflected in the share price.
- Recent news around the company has focused on its position within the biopharma space and how the market is reacting to its portfolio and pipeline updates, which helps frame the sharp recent moves. At the same time, analyst and investor commentary has increasingly centered on whether current expectations are conservative or optimistic given those developments.
- Right now, Kiniksa carries a valuation score of 2 out of 6. The rest of this article will compare different valuation methods to that score and then finish with a broader way to think about what the numbers really mean for you.
Kiniksa Pharmaceuticals International scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Kiniksa Pharmaceuticals International Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow (DCF) model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the business might be worth right now.
For Kiniksa Pharmaceuticals International, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $137.0 million. Analyst and model projections, all in $, point to free cash flow of $491.0 million by 2030. For the years 2026 through 2035, Simply Wall St combines analyst inputs for the nearer years and then extrapolates further cash flows to complete a 10 year path.
When those projected cash flows are discounted back, the DCF points to an estimated intrinsic value of about $199.62 per share. Compared with the recent share price around $52.99, this suggests the stock is roughly 73.5% undervalued according to this model.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Kiniksa Pharmaceuticals International is undervalued by 73.5%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.
Approach 2: Kiniksa Pharmaceuticals International Price vs Earnings
For a profitable company, the P/E ratio is a useful way to connect what you pay for the shares with what the business is currently earning. It helps you see how many dollars of share price the market is assigning to each dollar of earnings.
What counts as a “normal” P/E depends heavily on growth expectations and risk. Higher expected earnings growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually means investors look for a lower P/E to feel comfortable.
Kiniksa is trading on a P/E of 69.02x. That is well above the Biotechs industry average of 16.10x and also above the peer average of 12.77x. Simply Wall St’s Fair Ratio framework estimates what a more tailored P/E might look like for Kiniksa, based on factors such as its earnings growth profile, profit margins, industry, market cap and company specific risks. This produces a Fair Ratio of 23.64x.
The Fair Ratio is more specific to Kiniksa than a simple peer or industry comparison because it adjusts for the company’s own characteristics rather than relying on broad group averages. Comparing 69.02x with the 23.64x Fair Ratio suggests the shares are pricing in a richer earnings multiple than this model implies.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your Kiniksa Pharmaceuticals International Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Kiniksa Pharmaceuticals International’s business to a forecast for revenue, earnings and margins, and then to a Fair Value that you can compare with the current share price to help decide whether the stock looks attractive or stretched. All of this is available within an easy to use tool on the Community page that updates automatically when new news or earnings arrive. For example, one investor might align with a more optimistic Fair Value of US$68.00 that assumes higher growth from ARCALYST and newer programs, while another might prefer a more cautious Fair Value of US$38.00 that leans into concentration and competition risks. Narratives simply lay out these different stories side by side so you can see which assumptions fit your own view before making any decision.
For Kiniksa Pharmaceuticals International however we will make it really easy for you with previews of two leading Kiniksa Pharmaceuticals International Narratives:
🐂 Kiniksa Pharmaceuticals International Bull Case
Fair Value: US$68.00
Implied discount to this Fair Value: about 22.1% based on the recent share price of US$52.99
Revenue growth assumption: 25.8% a year
- Sees ARCALYST building deeper adoption across the recurrent pericarditis market, supported by patient access improvements and potential margin expansion.
- Leans on a broader pipeline of IL 1 focused therapies and digital tools to spread risk beyond a single product while aiming for higher long term earnings.
- Accepts meaningful risks around ARCALYST concentration, payer pushback, competition and R&D spend, but views these as manageable if current momentum holds.
🐻 Kiniksa Pharmaceuticals International Bear Case
Fair Value: US$50.00
Implied premium to this Fair Value: about 6.0% based on the recent share price of US$52.99
Revenue growth assumption: 21.1% a year
- Focuses on the reliance on a single flagship therapy and the possibility that new competitors or pricing shifts cap how much value ARCALYST can sustain over time.
- Highlights the risk that payer scrutiny, regulatory demands and high ongoing R&D costs could limit how much of projected revenue growth flows through to earnings.
- Assumes Kiniksa will still grow, but questions whether that growth justifies a richer P/E than many peers if margins, pricing or timelines fall short of expectations.
If you want to go beyond summaries and see every assumption that sits behind these views, you can review the full narratives on Simply Wall St, compare them with your own expectations for ARCALYST and the wider pipeline, then decide which story feels closest to your own thesis.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Kiniksa Pharmaceuticals International on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Do you think there's more to the story for Kiniksa Pharmaceuticals International? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com